Love Pharma Inc. (LUV.CN)
| Previous Close | 0.0300 |
| Open | 0.0250 |
| Bid | 0.0250 x N/A |
| Ask | 0.0300 x N/A |
| Day's Range | 0.0250 - 0.0250 |
| 52 Week Range | 0.0250 - 0.3000 |
| Volume | |
| Avg. Volume | 16,155 |
| Market Cap | 12.606M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0220 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 22, 2018 |
| 1y Target Est | N/A |
- ACCESSWIRE
Love Pharma Inc. Announces Share Consolidation
LOVE Pharma Inc. ("LOVE" and or "the Company") (CSE:LUV)(FSE:G1Q0)announced it intends to proceed with a consolidation of its common shares (each, a "Share") on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share (the "Consolidation").
- GlobeNewswire
InvestmentPitch Media Video Discusses LOVE Pharma’s Plans to Continue Developing a Portfolio of Innovative Products such as Naltrexone Encompassing Transdermal Drug Delivery Applications for Addictions and Long-COVID
VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug delivery applications. On October 11th, LOVE Pharma signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics, bringing significant IP related to the transdermal delivery of FDA approved Naltrexone, an opioid antagonist, primarily used to manage alcohol and or opioid use disorder
